Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Tanabe Obtains Right To Kidney Drug From Canadian Cytochroma

This article was originally published in PharmAsia News

Executive Summary

Mitsubishi Tanabe Pharmaceutical announced July 30 it signed a licensing agreement and obtained exclusive rights to develop and market CTA018 in the U.S. and Asia including Japan with Cytochroma, a Canadian bio-venture company. CTA018 is a vitamin D analog used to treat secondary hyperparathyroidis in patients with chronic kidney disease, and is entering Phase II development in Canada. According to the company, CTA018 is more effective in lowering parathormone compared to the current vitamin D analog. Cytochroma could receive up to CDN$105 million in up-front payments, milestone payments and an equity investment. (Click here for more - Japanese language
Advertisement

Related Content

Mitsubishi Tanabe’s Domestic Remicade Sales Jump 41.2 Percent, Result In Better Performance
Advertisement
UsernamePublicRestriction

Register

SC069186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel